Healthy Aging
healthy aging
Use of brain imaging data to improve prescriptions of psychotropic drugs - Examples of ketamine in depression and antipsychotics in schizophrenia
The use of molecular imaging, particularly PET and SPECT, has significantly transformed the treatment of schizophrenia with antipsychotic drugs since the late 1980s. It has offered insights into the links between drug target engagement, clinical effects, and side effects. A therapeutic window for receptor occupancy is established for antipsychotics, yet there is a divergence of opinions regarding the importance of blood levels, with many downplaying their significance. As a result, the role of therapeutic drug monitoring (TDM) as a personalized therapy tool is often underrated. Since molecular imaging of antipsychotics has focused almost entirely on D2-like dopamine receptors and their potential to control positive symptoms, negative symptoms and cognitive deficits are hardly or not at all investigated. Alternative methods have been introduced, i.e. to investigate the correlation between approximated receptor occupancies from blood levels and cognitive measures. Within the domain of antidepressants, and specifically regarding ketamine's efficacy in depression treatment, there is limited comprehension of the association between plasma concentrations and target engagement. The measurement of AMPA receptors in the human brain has added a new level of comprehension regarding ketamine's antidepressant effects. To ensure precise prescription of psychotropic drugs, it is vital to have a nuanced understanding of how molecular and clinical effects interact. Clinician scientists are assigned with the task of integrating these indispensable pharmacological insights into practice, thereby ensuring a rational and effective approach to the treatment of mental health disorders, signaling a new era of personalized drug therapy mechanisms that promote neuronal plasticity not only under pathological conditions, but also in the healthy aging brain.
Neural correlates of cognitive control across the adult lifespan
Cognitive control involves the flexible allocation of mental resources during goal-directed behaviour and comprises three correlated but distinct domains—inhibition, task shifting, and working memory. Healthy ageing is characterised by reduced cognitive control. Professor Cheryl Grady and her team have been studying the influence of age differences in large-scale brain networks on the three control processes in a sample of adults from 20 to 86 years of age. In this webinar, Professor Cheryl Grady will describe three aspects of this work: 1) age-related dedifferentiation and reconfiguration of brain networks across the sub-domains 2) individual differences in the relation of task-related activity to age, structural integrity and task performance for each sub-domain 3) modulation of brain signal variability as a function of cognitive load and age during working memory. This research highlights the reduction in dynamic range of network activity that occurs with ageing and how this contributes to age differences in cognitive control. Cheryl Grady is a senior scientist at the Rotman Research Institute at Baycrest, and Professor in the departments of Psychiatry and Psychology at the University of Toronto. She held the Canada Research Chair in Neurocognitive Aging from 2005-2018 and was elected as a Fellow of the Royal Society of Canada in 2019. Her research uses MRI to determine the role of brain network connectivity in cognitive ageing.
Phospholipid regulation in cognitive impairment and vascular dementia
An imbalance in lipid metabolism in neurodegeneration is still poorly understood. Phospholipids (PLs) have multifactorial participation in vascular dementia as Alzheimer, post-stroke dementia, CADASIL between others. Which include the hyperactivation of phospholipases, mitochondrial stress, peroxisomal dysfunction and irregular fatty acid composition triggering proinflammation in a very early stage of cognitive impairment. The reestablishment of physiological conditions of cholesterol, sphingolipids, phospholipids and others are an interesting therapeutic target to reduce the progression of AD. We propose the positive effect of BACE1 silencing produces a balance of phospholipid profile in desaturase enzymes-depending mode to reduce the inflammation response, and recover the cognitive function in an Alzheimer´s animal and brain stroke models. Pointing out there is a great need for new well-designed research focused in preventing phospholipids imbalance, and their consequent energy metabolism impairment, pro-inflammation and enzymatic over-processing, which would help to prevent unhealthy aging and AD progression.
Female brain and healthy aging: The pivotal role of the NPY-1R regulation
FENS Forum 2024
Longitudinal autophagy profiling of mammalian brain circuits reveals dynamic and sustained mitophagy throughout healthy aging
FENS Forum 2024